Genzyme reports positive long-term data for multiple sclerosis treatment
October 08, 2015 at 01:00 AM EDT
PARIS, Oct 8 (Reuters) - Genzyme, the rare disease unit of French drug company Sanofi, said on Thursday five-year investigational data from the extension study of its medication Lemtrada, sold in Europe and the United States, had shown positive results for patients with relapsing remitting multiple sclerosis.
